ClinicalTrials.gg
RecruitingNCT06916195CMV PEDUpdated Apr 6, 2026

Burden of Cytomegalovirus Reactivation in Pediatric Patients After Allogeneic Hematopoietic Stem Cell Transplantation

An observational study in Cytomegalovirus Infection and Hematopoietic Stem Cells Transplantation, sponsored by MSD Italia S.r.l.. Recruiting at 5 sites in Italy. Open to participants aged 0 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by MSD Italia S.r.l. (part of Merck & Co., Inc) · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
230
Ages
0 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Cytomegalovirus Infections with a site in Italy — 5 open to participants now, 6 under way, 1 of them phase 3. Cytomegalovirus Infections · Italy.

Started
2025
with 1 other
Observational
4 of 18
3 open now
Registered
17th of 18
by date
Lead sponsor
1 of 18
MSD Italia S.r.l.

Among the 18 studies in Cytomegalovirus Infections with a site in Italy, this one is one of 2 that started in 2025, is one of 4 observational ones, and was the 17th registered.

Cytomegalovirus Infections

370 studies on the registry are indexed under Cytomegalovirus Infections; 57 are open to participants now.

Browse Cytomegalovirus Infections studies →

Open to participants now

5 of the 18 studies in Cytomegalovirus Infections with a site in Italy are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 35 Cytomegalovirus Infections studies recruiting now, 20 (57%) set no upper age limit and 13 (37%) stop at 75 or younger; 19 take children under 18; 2 take healthy volunteers.

This study: 0 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Cytomegalovirus Infections with a site in Italy, or all of them as a file.
02

Study summary

This observational retrospective analysis will provide useful information for clinicians and payers, and local guidelines committee members, to improve the understanding of Cytomegalovirus clinical and economic burden and clinical management of pediatric patients undergoing allogeneic Hematopoietic Stem Cells Transplantation in Italy.

Read the detailed description

This is an observational retrospective analysis from the main pediatric centers in Italy (approximately 5 sites). The selected sites will be the most representative of Italy because they perform about 2/3 of all allogeneic HSCT per year.

Index date: date of allogeneic HSCT; retrospective data will be captured in consecutive patients undergoing allogeneic HSCT from January 2018 to June 2020 with maximum 12 months of follow-up for each patient. The data of the patients undergoing allogeneic HSCT after June 2020 will not be captured in order to avoid any possible bias due to off-label access to letermovir.

Medical Records (MR) will be used to describe the risk factors, patient characteristics, treatment patterns, and healthcare resource utilization of subjects who had a CMV infection.

Electronic or paper hospital charts (inpatient), clinical charts (inpatient and outpatient), and outpatient records will all be considered as MR for study purposes.

This is a secondary data collection study from electronic or paper medical chart review, no data from registry will be collected.

Patients (or their legally acceptable representatives) must have signed and dated the Informed Consent \& Privacy Form (ICF), if applicable.

03

Conditions studied

  • Cytomegalovirus Infection
  • Hematopoietic Stem Cells Transplantation
04

Who can participate

Ages eligible
0 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

About 230 patients from birth to less than 18 years of age allogeneic HSCT recipients at risk of developing CMV infection and/or disease who underwent allogeneic HSCT between January 2018 and June 2020 in the participating hospitals will be enrolled in the study. The selected hospitals will be the main ones in Italy based on the number of transplants performed every year and also considering the geographical distribution.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients from birth to less than 18 years of age (at the moment of the HSCT);
  • Patients who received allogeneic HSCT between January 2018 and June 2020;
  • Patients (or their legally acceptable representatives) must have signed and dated the \& Privacy Form (ICF), if applicable.

Exclusion criteria

Exclusion Criteria:

  • Letermovir use at any time
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
230 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Summary of demographic and baseline characteristics

    Description through frequencies and percentages (for categorical variables) and mean and median values, SD, quartiles, interquartile ranges and extreme values (for continuous variables).

    Time frame: at baseline (day of transplant)

  2. CMV Seroprevalence in the under 18 population undergoing allogeneic HSCT

    Proportion of patients CMV R+ at transplantation. CMV-seroprevalence and serostatus will be described according to the recipient or donor positivity. Comparisons will be conducted using the Chi-square or Fisher's exact test (for categorical variables), or the t-test or Wilcoxon rank sum test (for continuous variables).

    Time frame: at baseline (day of transplant)

  3. CMV serostatus

    R+/D-, R+/D+ and R-/D+ combination frequencies. CMV-seroprevalence and serostatus will be described according to the recipient or donor positivity. Comparisons will be conducted using the Chi-square or Fisher's exact test (for categorical variables), or the t-test or Wilcoxon rank sum test (for continuous variables).

    Time frame: at baseline (day of transplant)

  4. Donor type

    Allogeneic HSCT characteristics

    Time frame: at baseline (day of transplant)

  5. Stem cell source

    Allogeneic Hematopoietic Stem Cells Transplantation characteristics

    Time frame: at baseline (day of transplant)

  6. Conditioning intensity

    Allogeneic Hematopoietic Stem Cells Transplantation characteristics

    Time frame: at baseline (day of transplant)

  7. Underlying condition

    Allogeneic Hematopoietic Stem Cells Transplantation characteristics

    Time frame: at baseline (day of transplant)

  8. Usage of immunosuppression

    Allogeneic Hematopoietic Stem Cells Transplantation characteristics

    Time frame: at baseline (day of transplant)

  9. Current standard of care in CMV management in terms of PET approach

    It will be described quantitatively by tabulating frequencies and percentages.

    Time frame: during the first-year post-transplant

  10. Current standard of care in CMV management in terms of GCV prophylaxis

    It will be described quantitatively by tabulating frequencies and percentages.

    Time frame: during the first-year post-transplant

  11. Current standard of care in CMV management in terms of ACV prophylaxis

    It will be described quantitatively by tabulating frequencies and percentages.

    Time frame: during the first-year post-transplant

  12. Current standard of care in CMV management in terms of other

    It will be described quantitatively by tabulating frequencies and percentages.

    Time frame: during the first-year post-transplant

Secondary outcomes

  1. Rate of clinically significant CMV infection

    Incidence rates will be computed by dividing the number of events by the total number of person-years and then multiplying per 100. A Kaplan-Meier curve will describe the timing of first CS-CMVi and mortality.

    Time frame: at day +100, day +200 and during the first year post allogeneic HCT

  2. Median time to first CS-CMVi

    A Kaplan-Meier curve will describe the timing of first CS-CMVi and mortality.

    Time frame: during the first year after transplantation

  3. Rate of viral infections other than CMV

    Incidence rates will be computed by dividing the number of events by the total number of person-years and then multiplying per 100. A Kaplan-Meier curve will describe the timing of first CS-CMVi and mortality.

    Time frame: at day +100, day +200 and during the first year post allogeneic HCT

  4. Rate of bacterial infections

    Incidence rates will be computed by dividing the number of events by the total number of person-years and then multiplying per 100. A Kaplan-Meier curve will describe the timing of first CS-CMVi and mortality.

    Time frame: at day +100, day +200 and during the first year post allogeneic HCT

  5. Rate of fungal infections

    Incidence rates will be computed by dividing the number of events by the total number of person-years and then multiplying per 100. A Kaplan-Meier curve will describe the timing of first CS-CMVi and mortality.

    Time frame: at day +100, day +200 and during the first year post allogeneic HCT

  6. Allogeneic HSCT risk factors

    Underlying condition, donor type, stem cell source, conditioning intensity, immunosuppressive therapies. The relation between complications and risk factors will be analyzed through Cox regression models.

    Time frame: at baseline (day of transplant)

  7. CMV-related complications

    Proportion of patients with at least one CMV disease, "overall" and by type of disease, and number of diseases per patient. The relation between complications and risk factors will be analyzed through Cox regression models.

    Time frame: during the first-year post-transplant

  8. CMV-related complications

    Rate of acute and chronic Graft vs Host Disease Incidence rates will be computed by dividing the number of events by the total number of person-years and then multiplying per 100. A Kaplan-Meier curve will describe the timing of first CS-CMVi and mortality.

    Time frame: at day +100, day +200 and during the first year post allogeneic HCT

  9. CMV-related complications

    Rate of opportunistic infection declared by the investigator "CMV related-complication"

    Time frame: during the first-year post-transplant

  10. Number of hospitalizations and length of stay (LOS) after allogeneic HSCT

    Utilization of several healthcare resources will be described to quantify the economic burden. Data will include frequency of re-hospitalization, exams, diagnostic tests, visits, drugs use and the duration of re-hospitalization. Statistical tests (Chi-square, Fisher's exact, Student's T or Wilcoxon rank-sum) will be applied based on the variable type.

    Time frame: at day +100, day +200 and during the first year post allogeneic HCT

  11. All-cause mortality rate

    Kaplan-Meier curves will describe the timing of events.

    Time frame: at day +100, day +200 and during the first year post allogeneic HCT

07

Study locations

4 of 5 sites recruiting
  • IRCCS Istituto Giannina Gaslini, Trapianto di Cellule Staminali Emopoietiche, Dipartimento di Onco-Ematologia Pediatrica
    Genova, Italy
    Recruiting
  • Ospedale San Gerardo, Clinica Pediatrica
    Monza, 20900, Italy
    Recruiting
  • Azienda Ospedale-Università di Padova, Clinica di Oncoematologia Pediatrica
    Padova, 35128, Italy
    Not yet recruiting
  • IRCCS Ospedale Pediatrico Bambino Gesù, Dipartimento di Pediatria Ematologia e Oncologia
    Roma, 00165, Italy
    Recruiting
  • Ospedale Infantile Regina Margherita, Dipartimento Patologia e Cura del Bambino
    Torino, 10126, Italy
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Apr 2026, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2025
First posted
Apr 8, 2025
StartActual
May 9, 2025
Primary completionEst.
Apr 30, 2026
CompletionEst.
Jul 15, 2026
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06916195
Lead sponsor
MSD Italia S.r.l.
Responsible party
Sponsor
First posted
Apr 8, 2025
Start date
May 9, 2025
Primary completion
Apr 30, 2026 (estimated)
Completion
Jul 15, 2026 (estimated)
Last update
Apr 6, 2026

Study contacts

Antonia Maffucci
Contact
info.studiclinici@opisresearch.com
+39 03626331

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion